CN113133534A - Tranquilizing and relieving sustained-release oral liquid and preparation method thereof - Google Patents

Tranquilizing and relieving sustained-release oral liquid and preparation method thereof Download PDF

Info

Publication number
CN113133534A
CN113133534A CN202010063615.4A CN202010063615A CN113133534A CN 113133534 A CN113133534 A CN 113133534A CN 202010063615 A CN202010063615 A CN 202010063615A CN 113133534 A CN113133534 A CN 113133534A
Authority
CN
China
Prior art keywords
oral liquid
sodium hyaluronate
hyaluronate gel
extract
slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010063615.4A
Other languages
Chinese (zh)
Inventor
吴剑英
徐雯
周权
黄慧娟
陈晚华
张军东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Haohai Biological Technology Co ltd
Shanghai Likangrui Bioengineering Co ltd
Shanghai Jianhua Fine Biological Products Co ltd
Original Assignee
Shanghai Haohai Biological Technology Co ltd
Shanghai Likangrui Bioengineering Co ltd
Shanghai Jianhua Fine Biological Products Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haohai Biological Technology Co ltd, Shanghai Likangrui Bioengineering Co ltd, Shanghai Jianhua Fine Biological Products Co ltd filed Critical Shanghai Haohai Biological Technology Co ltd
Priority to CN202010063615.4A priority Critical patent/CN113133534A/en
Publication of CN113133534A publication Critical patent/CN113133534A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to the technical field of health-care food, and particularly relates to a tranquilization and slow release oral liquid and a preparation method thereof, wherein the oral liquid comprises the following components in percentage by weight: 0.7-9% of sodium hyaluronate gel, 0.1-5.5% of small molecular collagen, 0.1-3% of water-soluble chitosan, 0.1-1% of licorice extract, 0.1-1% of tremella polysaccharide, 0.03-1% of spina date seed extract, 0.03-3% of gamma-aminobutyric acid, 0.01-3% of hemp extract, 0.5-2% of food additive and the balance of water. The oral liquid prepared by the invention can effectively calm the central nervous system, improve sleep and simultaneously supplement nutrients necessary for human bodies.

Description

Tranquilizing and relieving sustained-release oral liquid and preparation method thereof
Technical Field
The invention belongs to the technical field of health-care food, and particularly relates to a calming and soothing sustained-release oral liquid and a preparation method thereof.
Background
With the progress of the times, the pace of life and work is highly tense, the work and life pressure of modern human beings rises year by year, and especially married and educated women and field women are generally characterized by easy anxiety and insomnia; meanwhile, with the coming of the aging age of China, the population of the old people is increased, and the old people are generally characterized by being easy to fall asleep.
The characteristics of the development of the economic society and the Chinese situation are a footfall point and a guide point for the development of market economy, and the basic physiological appeal of married fertile females, professional females and the elderly population at present is calmness, relaxation, anti-aging, beauty treatment, youth keeping and body building.
Hyaluronic Acid (HA) is a polysaccharide widely present in human tissues, is an unbranched polymeric glycosaminoglycan composed of repeating units of N-acetylglucosamine and D-glucuronosyl, is present in the intercellular spaces of animal tissues, and is present in high amounts in organs such as the skin, joint cavities, eyes, and the like. The HA is absorbed by oral administration through digestion, and researches show that the bioavailability is about 5 percent, the HA synthesis precursor in vivo can be increased, the HA synthesis amount in skin and other tissues is increased, the water retention property of the skin is improved, the skin is rich in elasticity, and wrinkles are reduced. In addition, the sodium hyaluronate with a certain high molecular weight not only has the effect of improving skin moisture, but also can slowly release medicines to play a role; the sodium hyaluronate with low molecular weight is easy to be quickly absorbed by human body, and has the effects of quickly supplementing skin moisture and increasing skin elasticity.
Gamma-aminobutyric acid (GABA), a natural amino acid, is a major neurotransmitter that acts in the central nervous system of mammals and mediates nearly half of inhibitory neurotransmission. A large number of experimental studies prove that GABA has the function of improving sleep, and mouse experimental data show that the GABA can prolong the sleep time and increase the number of animals falling asleep at subthreshold dose after being orally taken. In addition, there are also research results by japanese scholars showing that GABA has a cosmetic effect.
The water soluble chitosan is widely present in the cells of lower plant fungi and algae, shells of crustaceans, shrimps, crabs and insects, cell walls of higher plants and the like, and has the functions of resisting cancers and improving immunity.
The semen Ziziphi Spinosae is dry mature seed of Rhamnaceae plant cortex Choerospondiatis, belongs to Chinese medicinal materials, is mainly used for treating symptoms such as vexation, insomnia, cardiopalmus, asthenia and hyperhidrosis, and has effects of nourishing liver, calming heart, arresting sweating, and promoting fluid production. A large number of pharmacological research and clinical medication results show that the spina date seed can effectively prolong the sleep time, has a good synergistic effect with the sedative-hypnotic drugs such as pentobarbital and the like, and has a good curative effect on people with difficulty in falling asleep and easy sleep awakening.
Tremella polysaccharide is an acidic heteropolysaccharide obtained from Tremella sporophore, and has main chain structure of mannan connected by alpha- (1 → 3) glycosidic bond, and branched chain composed of glucuronic acid and xylose. Acidic heteropolysaccharide existing in deep fermented sporophyte of Tremella; the Tremella polysaccharide is basidiomycete polysaccharide immunopotentiator, and has functions of improving organism immunity and increasing leukocyte. Can significantly improve the phagocytic function of reticuloendothelial cells of experimental animals, promote nonspecific immunity, and improve the level of immunoglobulin and serum total complement. Can be used for preventing and treating bone marrow depression caused by radiation and antineoplastic agent (such as CTX), and promoting synthesis of protein in liver.
Small molecule collagen refers to collagen biological high molecular substance with molecular weight below 2000 Dalton, which is collagen existing in form of small peptide and can be directly absorbed by human body without decomposition
The licorice extract is a component extracted from licorice and having medicinal value. The Glycyrrhrizae radix extract generally comprises glycyrrhizin, glycyrrhizic acid, liquiritin, glycyrrhizin, licoflavonoids, semaphorin, formononetin, quercetin, etc. As a yellow to brown-yellow powder. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing the medicines. Can be used for treating weakness of spleen and stomach, asthenia, palpitation, short breath, cough, excessive phlegm, abdominal distention, and spasm and pain of limbs.
Cannabis extracts, a plant dietary supplement containing Cannabidiol (CBD), have generated an increasing interest in Cannabidiol (CBD) containing beverages as consumers are concerned about CBD, a derivative of cannabis, as a health supplement, with the recent passage of farm acts. In addition, the continuing worldwide trend toward the legalization of cannabis is creating a need for "hard" cannabis drinks. Several studies have shown that CBD can help treat inflammation, pain, anxiety and seizures.
Disclosure of Invention
The invention mainly provides a tranquilization and slow release oral liquid and a preparation method thereof, which can effectively calm the central nervous system, improve sleep and supplement nutrients necessary for a human body.
The technical scheme is as follows:
a tranquilization and slow release oral liquid comprises the following components in percentage by weight: 0.7-9% of sodium hyaluronate gel, 0.1-5.5% of small molecular collagen, 0.1-3% of water-soluble chitosan, 0.1-1% of licorice extract, 0.1-1% of tremella polysaccharide, 0.03-1% of spina date seed extract, 0.03-3% of gamma-aminobutyric acid, 0.01-3% of hemp extract, 0.5-2% of food additive and the balance of water.
Preferably, the sodium hyaluronate gel is formed by combining 200-500 ten thousand Da high molecular weight sodium hyaluronate gel, 10-150 ten thousand Da medium molecular weight sodium hyaluronate gel and 0.4-5 ten thousand Da low molecular weight sodium hyaluronate gel, and the content of the high molecular weight sodium hyaluronate gel in the oral liquid is 0.1-1%, the content of the medium molecular weight sodium hyaluronate gel is 0.1-3% and the content of the low molecular weight sodium hyaluronate gel is 0.5-5%.
Preferably, the oral liquid comprises the following components in percentage by weight: 0.3% of 450 ten thousand Da sodium hyaluronate gel, 0.5% of 40 ten thousand Da sodium hyaluronate gel, 2% of 1.5 ten thousand Da sodium hyaluronate gel, 2% of small molecular collagen, 1% of water-soluble chitosan, 0.6% of licorice extract, 0.5% of tremella polysaccharide, 0.5% of spina date seed extract, 0.5% of gamma-aminobutyric acid, 1% of hemp extract, 1% of food additive and the balance of deionized water.
Preferably, the food additive is one or more selected from aspartame, citric acid, HPMC, acesulfame potassium, lactic acid, sodium citrate, sodium tripolyphosphate, guar gum, xanthan gum, nisin, thickening agent, maltodextrin, dietary fiber, non-dairy creamer and sour agent.
Preferably, the oral liquid is a liquid gel-like sustained-release preparation, and the particle size of the gel sustained-release preparation is 30-300 nm.
The preparation method of the tranquilizing and slow-releasing oral liquid comprises the following steps:
(1) weighing micromolecular collagen, water-soluble chitosan, a liquorice extract, tremella polysaccharide, a spina date seed extract, gamma-aminobutyric acid, a hemp extract and a food additive according to the formula ratio, dissolving in deionized water, and uniformly mixing;
(2) adding sodium hyaluronate gel, regulating osmotic pressure to 7-8 with isoosmotic adjusting agent, and sterilizing the mixed solution by wet heat to obtain the tranquilizing and slow-releasing oral liquid.
By adopting the scheme, the invention has the following advantages:
(1) the oral liquid prepared by the invention contains the sodium hyaluronate gel with high, medium and low molecular weights, and the sodium hyaluronate gel wraps the medicinal ingredients, so that the medicinal properties can be slowly released, the action time of the medicament is prolonged, the medicinal effect time is long, the particle size of the gel is 30-300nm, the gel can act on a plurality of pathological parts, and no foreign body sensation exists;
(2) the oral liquid has good taste, can effectively calm central nervous system, improve sleep, and supplement essential nutrients, and has remarkable intestinal tract care and skin caring effects.
Detailed Description
The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental reagents and materials involved are conventional biochemical reagents and materials unless otherwise specified.
Example 1
The preparation process of the tranquilizing and slow-releasing oral liquid comprises the following steps:
(1) weighing 2 wt% of micromolecular collagen, 1 wt% of water-soluble chitosan, 0.6 wt% of liquorice extract, 0.5 wt% of tremella polysaccharide, 0.5 wt% of spina date seed extract, 0.5 wt% of gamma-aminobutyric acid, 1 wt% of hemp extract and 1 wt% of food additive, dissolving in deionized water, and uniformly mixing;
(2) adding 0.3 wt% of 450 ten thousand Da sodium hyaluronate gel, 0.5 wt% of 40 ten thousand Da sodium hyaluronate gel and 2 wt% of 1.5 ten thousand Da sodium hyaluronate gel, regulating osmotic pressure to 7.35 by using phosphate buffer solution, and then carrying out moist heat sterilization on the mixed solution to obtain the calm, slow and sustained release oral liquid.
Example 2
The preparation process of the tranquilizing and slow-releasing oral liquid comprises the following steps:
(1) weighing 5 wt% of micromolecular collagen, 0.1 wt% of water-soluble chitosan, 1 wt% of liquorice extract, 1 wt% of tremella polysaccharide, 0.8 wt% of spina date seed extract, 0.03 wt% of gamma-aminobutyric acid, 3 wt% of hemp extract and 0.5 wt% of food additive, dissolving in deionized water, and uniformly mixing;
(2) adding 0.7 wt% of 200 kilomega Da sodium hyaluronate gel, 2 wt% of 100 kilomega Da sodium hyaluronate gel and 0.5 wt% of 5 kilomega Da sodium hyaluronate gel, regulating osmotic pressure to 7.0 by using phosphate buffer solution, and then carrying out moist heat sterilization on the mixed solution to obtain the tranquilization and slow release oral liquid.
Example 3
The preparation process of the tranquilizing and slow-releasing oral liquid comprises the following steps:
(1) weighing 0.1 wt% of micromolecular collagen, 0.1 wt% of water-soluble chitosan, 1 wt% of liquorice extract, 0.1 wt% of tremella polysaccharide, 1 wt% of spina date seed extract, 2 wt% of gamma-aminobutyric acid, 0.01 wt% of hemp extract and 2 wt% of food additive, dissolving in deionized water, and uniformly mixing;
(2) adding 0.1 wt% of 500 kiloda sodium hyaluronate gel, 0.1 wt% of 10 kiloda sodium hyaluronate gel and 5 wt% of 4000 kiloda sodium hyaluronate gel, regulating osmotic pressure to 8.0 by using phosphate buffer solution, and then carrying out damp-heat sterilization on the mixed solution to obtain the tranquilization and slow release oral liquid.
Example 4
The preparation process of the tranquilizing and slow-releasing oral liquid comprises the following steps:
(1) weighing 5.5 wt% of micromolecular collagen, 3 wt% of water-soluble chitosan, 0.1 wt% of liquorice extract, 0.8 wt% of tremella polysaccharide, 0.03 wt% of spina date seed extract, 3 wt% of gamma-aminobutyric acid, 3 wt% of hemp extract and 0.5 wt% of food additive, dissolving in deionized water, and uniformly mixing;
(2) adding 1 wt% of 250 ten thousand Da sodium hyaluronate gel, 1 wt% of 50 ten thousand Da sodium hyaluronate gel and 2 wt% of 1 ten thousand Da sodium hyaluronate gel, regulating osmotic pressure to 7.5 by using a phosphate buffer solution, and then carrying out damp-heat sterilization on the mixed solution to obtain the tranquilizing and slow-releasing oral liquid.
Comparative example 1
This comparative example differs from example 1 in that no spine date seed extract is present.
Comparative example 2
This comparative example differs from example 1 in that it does not contain cannabis extract.
Comparative example 3
This comparative example differs from example 1 in that it does not contain gamma-aminobutyric acid.
Comparative example 4
This comparative example differs from example 1 in that it does not contain tremella polysaccharide.
Animal experiments
60 rats of the same age were selected, 40 for the experiment, 10 for normal control and 10 for blank control. 40 experimental rats were administered the oral liquids of example 1, comparative example 2 and comparative example 3, respectively, 1 time per day for one month continuously, and the normal control group was administered drinking water and the blank control group was not treated. After 1h of each administration, the experimental group and the normal control group were simultaneously subjected to a startle treatment. After 24h after the last startle treatment, venous blood of rats was collected and the serum epinephrine content was measured, and the results are shown in table 1.
TABLE 1 rat serum epinephrine results
Figure BDA0002375281960000061
Figure BDA0002375281960000071
As can be seen from Table 1, the increase of adrenaline in the serum of the rats of example 1 was least significant compared with those of comparative examples 1 to 3 and the normal control group, indicating that the oral liquid has a soothing and soothing effect.
Various other modifications and changes may be made by those skilled in the art based on the above-described technical solutions and concepts, and all such modifications and changes should fall within the scope of the claims of the present invention.

Claims (6)

1. A tranquilization and slow release oral liquid comprises the following components in percentage by weight: 0.7-9% of sodium hyaluronate gel, 0.1-5.5% of small molecular collagen, 0.1-3% of water-soluble chitosan, 0.1-1% of licorice extract, 0.1-1% of tremella polysaccharide, 0.03-1% of spina date seed extract, 0.03-3% of gamma-aminobutyric acid, 0.01-3% of hemp extract, 0.5-2% of food additive and the balance of water.
2. The tranquilizing slow-release oral liquid according to claim 1, wherein: the sodium hyaluronate gel is formed by combining 200-500 ten thousand Da high molecular weight sodium hyaluronate gel, 10-150 ten thousand Da medium molecular weight sodium hyaluronate gel and 0.4-5 ten thousand Da low molecular weight sodium hyaluronate gel, and the content of the high molecular weight sodium hyaluronate gel in the oral liquid is 0.1-1%, the content of the medium molecular weight sodium hyaluronate gel in the oral liquid is 0.1-3%, and the content of the low molecular weight sodium hyaluronate gel in the oral liquid is 0.5-5%.
3. The tranquilizing slow-release oral liquid according to claim 2, wherein: the paint comprises the following components in percentage by weight: 0.3% of 450 ten thousand Da sodium hyaluronate gel, 0.5% of 40 ten thousand Da sodium hyaluronate gel, 2% of 1.5 ten thousand Da sodium hyaluronate gel, 2% of small molecular collagen, 1% of water-soluble chitosan, 0.6% of licorice extract, 0.5% of tremella polysaccharide, 0.5% of spina date seed extract, 0.5% of gamma-aminobutyric acid, 1% of hemp extract, 1% of food additive and the balance of deionized water.
4. The tranquilizing slow-release oral liquid according to claim 1, wherein: the food additive is one or more selected from aspartame, citric acid, HPMC, acesulfame, lactic acid, sodium citrate, sodium tripolyphosphate, guar gum, xanthan gum, nisin, thickener, maltodextrin, dietary fiber, vegetable fat powder and sour agent.
5. The tranquilizing slow-release oral liquid according to claim 1, wherein: the oral liquid is a liquid gel-like sustained-release preparation, and the particle size of the gel sustained-release preparation is 30-300 nm.
6. A process for preparing a soothing slow-release oral liquid according to claim 1, wherein: the method comprises the following steps:
(1) weighing micromolecular collagen, water-soluble chitosan, a liquorice extract, tremella polysaccharide, a spina date seed extract, gamma-aminobutyric acid, a hemp extract and a food additive according to the formula ratio, dissolving in deionized water, and uniformly mixing;
(2) adding sodium hyaluronate gel, regulating osmotic pressure to 7-8 with isoosmotic adjusting agent, and sterilizing the mixed solution by wet heat to obtain the tranquilizing and slow-releasing oral liquid.
CN202010063615.4A 2020-01-20 2020-01-20 Tranquilizing and relieving sustained-release oral liquid and preparation method thereof Pending CN113133534A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010063615.4A CN113133534A (en) 2020-01-20 2020-01-20 Tranquilizing and relieving sustained-release oral liquid and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010063615.4A CN113133534A (en) 2020-01-20 2020-01-20 Tranquilizing and relieving sustained-release oral liquid and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113133534A true CN113133534A (en) 2021-07-20

Family

ID=76808827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010063615.4A Pending CN113133534A (en) 2020-01-20 2020-01-20 Tranquilizing and relieving sustained-release oral liquid and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113133534A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113679046A (en) * 2021-08-20 2021-11-23 华熙生物科技股份有限公司 Composition for promoting interaction of hyaluronic acid and collagen and application thereof
CN113966840A (en) * 2021-10-29 2022-01-25 绿优品(福建)健康科技研发中心有限公司 Hyaluronic acid beverage capable of soothing nerves and promoting sleep and preparation method thereof
WO2023078378A1 (en) * 2021-11-04 2023-05-11 华熙生物科技股份有限公司 Composition containing hyaluronic acids or salts thereof for improving immunity of organism and promoting health of gastrointestinal tract, and use thereof
IT202200015375A1 (en) * 2022-07-21 2024-01-21 Vivatis Pharma Italia S R L A novel high molecular weight hyaluronic acid or its salt of plant origin for use in maintaining joint homeostasis and preventing the damaging processes of osteoarthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王新兰: "《吸毒行为矫治》", 31 August 2012, 华中科技大学出版社 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113679046A (en) * 2021-08-20 2021-11-23 华熙生物科技股份有限公司 Composition for promoting interaction of hyaluronic acid and collagen and application thereof
CN113679046B (en) * 2021-08-20 2024-03-08 华熙生物科技股份有限公司 Composition for promoting interaction of hyaluronic acid and collagen and application thereof
CN113966840A (en) * 2021-10-29 2022-01-25 绿优品(福建)健康科技研发中心有限公司 Hyaluronic acid beverage capable of soothing nerves and promoting sleep and preparation method thereof
WO2023078378A1 (en) * 2021-11-04 2023-05-11 华熙生物科技股份有限公司 Composition containing hyaluronic acids or salts thereof for improving immunity of organism and promoting health of gastrointestinal tract, and use thereof
IT202200015375A1 (en) * 2022-07-21 2024-01-21 Vivatis Pharma Italia S R L A novel high molecular weight hyaluronic acid or its salt of plant origin for use in maintaining joint homeostasis and preventing the damaging processes of osteoarthritis
WO2024018437A1 (en) * 2022-07-21 2024-01-25 VIVATIS PHARMA ITALIA S.r.l. A new high molecular weight of hyaluronic acid or salt thereof of plant origin for use in maintaining joint homeostasis and preventing the harmful processes of osteoarthritis.

Similar Documents

Publication Publication Date Title
CN113133534A (en) Tranquilizing and relieving sustained-release oral liquid and preparation method thereof
CN103142759A (en) Oral liquid capable of complementing vital essence and tonifying Qi and nourishing blood and tranquilization
CN102172269B (en) Hidegelatin fabricated food with beautification function
CN102823885B (en) Sea cucumber chewable tablets and preparation method thereof
CN104432035B (en) The health nutrient composition and method of making the same of enhancing immunity and application
CN104586669A (en) Fat-reducing externally-applied cream
CN106551398A (en) A kind of anti-aging cream taste and preparation method thereof
CN107455625A (en) A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function
CN107373672A (en) A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof
CN101805688B (en) Mulberry health-care wine and preparation method thereof
CN104814901A (en) Striae gravidarum preventing gel and preparation method thereof
CN108740863A (en) A kind of composition of blood-enrich and its preparation method and application
CN103750094A (en) Male hachinoko health-care paste and preparation method thereof
CN101439124B (en) Method for preparing composite big fruit sea-buckthorn anti-aging powder
CN105920198B (en) Cell wall-broken micropowder with blood replenishing effect and preparation method thereof
CN103053767B (en) Method for preparing desert cistanche health-care nutrition tea
CN111227143A (en) Sparassis crispa health-care beverage and preparation method thereof
CN108815505A (en) Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting
CN107281084A (en) A kind of whitening Chinese medicament mask and preparation method thereof
CN103798791A (en) Composition for benefiting qi and nourishing blood
CN1718011A (en) Method for preparing sour milk contg. micron ginseng and antler etc. with tonifying-kidney and eliminating fatigue functions
CN106942561A (en) A kind of beverage composition for treating dental erosion and preparation method and application
CN102784230A (en) Pharmaceutical composition preparation for treating nutritional anemia
CN103181557A (en) Nutritious food with slimming function and preparation method thereof
KR101048939B1 (en) Method for producing product for promoting hair growth

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210720

RJ01 Rejection of invention patent application after publication